Shattuck Labs to Attend Investor Conferences Scheduled for December
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 20 2025
0mins
Source: Newsfilter
Company Overview: Shattuck Labs, Inc. is a clinical-stage biotechnology company focused on developing novel therapeutics targeting TNF superfamily receptors for inflammatory and immune-mediated diseases, with a lead program, SL-325, currently in Phase 1 clinical trials.
Upcoming Conferences: The company's management, led by CEO Taylor Schreiber, will participate in the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025, and the Evercore ISI 8th Annual HealthCONx Conference on December 4, 2025, featuring presentations and one-on-one meetings.
SL-325 Details: SL-325 is a potential first-in-class DR3 blocking antibody designed for a complete blockade of the DR3/TL1A pathway, showing high affinity and superior activity in preclinical studies, with a favorable safety profile in non-human primates.
Investor Relations: For more information, interested parties can visit Shattuck Labs' website or contact Andrew R. Neill, the Chief Financial Officer, for investor inquiries.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy STTK?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on STTK
Wall Street analysts forecast STTK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for STTK is 5.00 USD with a low forecast of 4.00 USD and a high forecast of 6.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
2 Buy
2 Hold
0 Sell
Moderate Buy
Current: 4.070
Low
4.00
Averages
5.00
High
6.00
Current: 4.070
Low
4.00
Averages
5.00
High
6.00
About STTK
Shattuck Labs, Inc. is a biotechnology company. The Company is engaged in the development of treatments for inflammatory and immune-mediated diseases. Its lead product candidate, SL-325, is a monoclonal antibody that is designed to bind to death receptor 3 (DR3) and inhibit its interaction with its ligand, TL1A. TL1A is a costimulatory ligand in the tumor necrosis factor superfamily, which activates immune responses through binding a single receptor, DR3. The Company is conducting a Phase I clinical trial in healthy volunteers. In addition, the Company is also developing SL-425, a half-life extended version of SL-325. It is also developing multiple preclinical DR3-based bispecific antibodies, which are designed to inhibit both the DR3/TL1A axis and another biologically relevant target for the treatment of patients with inflammatory bowel disease.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Shattuck Labs Shares Rise After Piper Sandler Initiates Overweight Rating
- Rating Upgrade: Piper Sandler initiates coverage on Shattuck Labs (STTK) with an Overweight rating and a $15 price target, likely driving an increase in the company's stock price.
- Clinical Trial Catalysts: Analyst Yasmeen Rahimi highlights that Shattuck's lead candidate SL-325 is set to report initial Phase 1 trial results in Q2 and initiate mid-stage trials in Q3, presenting significant market opportunities for the company.
- Mechanism Validation: The mechanism of action for SL-325 has been validated by nearly eight drugs targeting TL1A, a protein that causes inflammation through interaction with the DR3 receptor, which Shattuck's candidate aims to block, providing durable inflammation protection.
- Differentiated Treatment: The analyst notes that SL-325 offers a differentiated approach to treating inflammatory bowel disease patients, expected to have a greater inhibitory effect, thereby enhancing its competitive position in the market.
Continue Reading
Latest Rating Changes on Wall Street
- Mizuho Upgrades Applied Materials: Mizuho upgrades Applied Materials (AMAT) to Outperform from Neutral, raising the price target to $370, reflecting confidence in the semiconductor company's accelerating growth, which is expected to boost its stock price.
- Jefferies Downgrades BJ's Wholesale: Jefferies downgrades BJ's Wholesale from Buy to Hold, citing slower growth and increased risks in competitive markets, which may lead to underperformance and affect investor sentiment.
- Morgan Stanley Upgrades Johnson & Johnson: Morgan Stanley upgrades Johnson & Johnson (JNJ) to Overweight with a price target increase to $252, based on expectations of new product contributions and a higher P/E ratio, likely driving future earnings growth.
- Barclays Initiates TPG as Overweight: Barclays initiates TPG with an Overweight rating, highlighting its strong positioning for medium-term growth in a recovering capital markets environment, which is expected to attract more investor interest.
Continue Reading